Literature DB >> 6801128

The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.

E Pearlstein, J Sorvillo, I Gigli.   

Abstract

Fibronectin is a normal plasma protein that enhances reticuloendothelial system functioning, and may participate in immune complex clearance. The interaction of 125I-fibronectin with human C1 and C1q in vitro was investigated by employing a highly reproducible solid-phase binding assay in microtiter wells. We demonstrated that although fibronectin does not bind to antigen-antibody complex (BSA-anti-BSA) or immune complexes containing C1, a 20-fold increase in binding was obtained when the complexes contained C1q alone. In the absence of antigen-antibody complexes, fibronectin binds to the C1q fixed to the wells in a dose-response fashion but not to intact C1. C1q in the fluid phase inhibits 85% of the fibronectin binding to immobilized C1q. The amount of fibronectin bound by immobilized C1q or gelatin is approximately equal. The binding of fibronectin to C1q could be inhibited by the restoration of C1r + C1s to the C1 macromolecular complex before the addition of fibronectin. The inhibition was dependent on the concentration of C1r + C1s and achieved a maximum of 70% at 100 micrograms/ml. This inhibition could be reversed by the removal of C1r and C1s subunits with EDTA or C1 inhibitor. Digestion of C1q with pepsin resulted in an 85% loss of fibronectin binding. It therefore appears that at least one site of fibronectin binding to C1q is in the globular portion of this complement component.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6801128

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes.

Authors:  M T Rimoldi; A J Tenner; D A Bobak; K A Joiner
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

2.  C1q binding to human vascular smooth muscle cells mediates immune complex deposition and superoxide generation.

Authors:  M Shingu; K Yoshioka; M Nobunaga; T Motomatu
Journal:  Inflammation       Date:  1989-10       Impact factor: 4.092

3.  The C1q subunit of the first component of complement binds to laminin: a mechanism for the deposition and retention of immune complexes in basement membrane.

Authors:  J F Bohnsack; A J Tenner; G W Laurie; H K Kleinman; G R Martin; E J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  Serum levels of RHP and of unbound C1q in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  C L Rosano; N Parhami; K E Hechemy; C Hurwitz
Journal:  Inflammation       Date:  1988-08       Impact factor: 4.092

5.  Cross-linking of fibronectin to collagenous proteins.

Authors:  D F Mosher
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

6.  Affinity of myeloma IgG proteins for fibronectin.

Authors:  A Hautanen; J Keski-Oja
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

7.  Studies on fibronectin in inflammatory vs non-inflammatory polymorphonuclear leucocytes of patients with rheumatoid arthritis. II. Synthesis and release of fibronectin in vitro.

Authors:  C Menard; A D Beaulieu; M Audette; J Corbeil; L Latulippe
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

8.  The role of fibronectin in the cryoprecipitation of monoclonal cryoglobulins.

Authors:  J Strevey; A D Beaulieu; C Ménard; J P Valet; L Latulippe; J Hébert
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

9.  Affinity of fibronectin for polyclonal IgG.

Authors:  M Salvarrey; A Rostagno
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

10.  Antibody-independent interactions of fibronectin, C1q, and human neutrophils with Treponema pallidum.

Authors:  R E Baughn
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.